348 related articles for article (PubMed ID: 33182542)
1. AXL Receptor in Breast Cancer: Molecular Involvement and Therapeutic Limitations.
Falcone I; Conciatori F; Bazzichetto C; Bria E; Carbognin L; Malaguti P; Ferretti G; Cognetti F; Milella M; Ciuffreda L
Int J Mol Sci; 2020 Nov; 21(22):. PubMed ID: 33182542
[TBL] [Abstract][Full Text] [Related]
2. Giving AXL the axe: targeting AXL in human malignancy.
Gay CM; Balaji K; Byers LA
Br J Cancer; 2017 Feb; 116(4):415-423. PubMed ID: 28072762
[TBL] [Abstract][Full Text] [Related]
3. AXL receptor tyrosine kinase as a promising anti-cancer approach: functions, molecular mechanisms and clinical applications.
Zhu C; Wei Y; Wei X
Mol Cancer; 2019 Nov; 18(1):153. PubMed ID: 31684958
[TBL] [Abstract][Full Text] [Related]
4. Targeting Axl favors an antitumorigenic microenvironment that enhances immunotherapy responses by decreasing Hif-1α levels.
Goyette MA; Elkholi IE; Apcher C; Kuasne H; Rothlin CV; Muller WJ; Richard DE; Park M; Gratton JP; Côté JF
Proc Natl Acad Sci U S A; 2021 Jul; 118(29):. PubMed ID: 34266948
[TBL] [Abstract][Full Text] [Related]
5. Axl and Mer Receptor Tyrosine Kinases: Distinct and Nonoverlapping Roles in Inflammation and Cancer?
Dransfield I; Farnworth S
Adv Exp Med Biol; 2016; 930():113-32. PubMed ID: 27558819
[TBL] [Abstract][Full Text] [Related]
6. AXL induces epithelial-to-mesenchymal transition and regulates the function of breast cancer stem cells.
Asiedu MK; Beauchamp-Perez FD; Ingle JN; Behrens MD; Radisky DC; Knutson KL
Oncogene; 2014 Mar; 33(10):1316-24. PubMed ID: 23474758
[TBL] [Abstract][Full Text] [Related]
7. Warfarin Blocks Gas6-Mediated Axl Activation Required for Pancreatic Cancer Epithelial Plasticity and Metastasis.
Kirane A; Ludwig KF; Sorrelle N; Haaland G; Sandal T; Ranaweera R; Toombs JE; Wang M; Dineen SP; Micklem D; Dellinger MT; Lorens JB; Brekken RA
Cancer Res; 2015 Sep; 75(18):3699-705. PubMed ID: 26206560
[TBL] [Abstract][Full Text] [Related]
8. AXL Targeting Overcomes Human Lung Cancer Cell Resistance to NK- and CTL-Mediated Cytotoxicity.
Terry S; Abdou A; Engelsen AST; Buart S; Dessen P; Corgnac S; Collares D; Meurice G; Gausdal G; Baud V; Saintigny P; Lorens JB; Thiery JP; Mami-Chouaib F; Chouaib S
Cancer Immunol Res; 2019 Nov; 7(11):1789-1802. PubMed ID: 31488404
[TBL] [Abstract][Full Text] [Related]
9. MicroRNA 34a-AXL Axis Regulates Vasculogenic Mimicry Formation in Breast Cancer Cells.
Lim D; Cho JG; Yun E; Lee A; Ryu HY; Lee YJ; Yoon S; Chang W; Lee MS; Kwon BS; Kim J
Genes (Basel); 2020 Dec; 12(1):. PubMed ID: 33374832
[TBL] [Abstract][Full Text] [Related]
10. Axl kinase as a key target for oncology: focus on small molecule inhibitors.
Feneyrolles C; Spenlinhauer A; Guiet L; Fauvel B; Daydé-Cazals B; Warnault P; Chevé G; Yasri A
Mol Cancer Ther; 2014 Sep; 13(9):2141-8. PubMed ID: 25139999
[TBL] [Abstract][Full Text] [Related]
11. TAM receptor tyrosine kinases: biologic functions, signaling, and potential therapeutic targeting in human cancer.
Linger RM; Keating AK; Earp HS; Graham DK
Adv Cancer Res; 2008; 100():35-83. PubMed ID: 18620092
[TBL] [Abstract][Full Text] [Related]
12. Axl inhibitors as novel cancer therapeutic agents.
Shen Y; Chen X; He J; Liao D; Zu X
Life Sci; 2018 Apr; 198():99-111. PubMed ID: 29496493
[TBL] [Abstract][Full Text] [Related]
13. AXL is a key regulator of inherent and chemotherapy-induced invasion and predicts a poor clinical outcome in early-stage colon cancer.
Dunne PD; McArt DG; Blayney JK; Kalimutho M; Greer S; Wang T; Srivastava S; Ong CW; Arthur K; Loughrey M; Redmond K; Longley DB; Salto-Tellez M; Johnston PG; Van Schaeybroeck S
Clin Cancer Res; 2014 Jan; 20(1):164-75. PubMed ID: 24170546
[TBL] [Abstract][Full Text] [Related]
14. The receptor tyrosine kinase Axl in cancer: biological functions and therapeutic implications.
Paccez JD; Vogelsang M; Parker MI; Zerbini LF
Int J Cancer; 2014 Mar; 134(5):1024-33. PubMed ID: 23649974
[TBL] [Abstract][Full Text] [Related]
15. Taking aim at Mer and Axl receptor tyrosine kinases as novel therapeutic targets in solid tumors.
Linger RM; Keating AK; Earp HS; Graham DK
Expert Opin Ther Targets; 2010 Oct; 14(10):1073-90. PubMed ID: 20809868
[TBL] [Abstract][Full Text] [Related]
16. Key Roles of AXL and MER Receptor Tyrosine Kinases in Resistance to Multiple Anticancer Therapies.
Schoumacher M; Burbridge M
Curr Oncol Rep; 2017 Mar; 19(3):19. PubMed ID: 28251492
[TBL] [Abstract][Full Text] [Related]
17. Axl receptor tyrosine kinase is up-regulated in metformin resistant prostate cancer cells.
Bansal N; Mishra PJ; Stein M; DiPaola RS; Bertino JR
Oncotarget; 2015 Jun; 6(17):15321-31. PubMed ID: 26036314
[TBL] [Abstract][Full Text] [Related]
18. The Receptor Tyrosine Kinase AXL Is Required at Multiple Steps of the Metastatic Cascade during HER2-Positive Breast Cancer Progression.
Goyette MA; Duhamel S; Aubert L; Pelletier A; Savage P; Thibault MP; Johnson RM; Carmeliet P; Basik M; Gaboury L; Muller WJ; Park M; Roux PP; Gratton JP; Côté JF
Cell Rep; 2018 May; 23(5):1476-1490. PubMed ID: 29719259
[TBL] [Abstract][Full Text] [Related]
19. Targeting AXL overcomes resistance to docetaxel therapy in advanced prostate cancer.
Lin JZ; Wang ZJ; De W; Zheng M; Xu WZ; Wu HF; Armstrong A; Zhu JG
Oncotarget; 2017 Jun; 8(25):41064-41077. PubMed ID: 28455956
[TBL] [Abstract][Full Text] [Related]
20. Combined inhibition of AXL, Lyn and p130Cas kinases block migration of triple negative breast cancer cells.
Pénzes K; Baumann C; Szabadkai I; Orfi L; Kéri G; Ullrich A; Torka R
Cancer Biol Ther; 2014; 15(11):1571-82. PubMed ID: 25482942
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
